
Kamlesh Khunti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11671712/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
2	Type 2 diabetes. Lancet, The, 2017, 389, 2239-2251.	13.7	1,691
3	Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ: British Medical Journal, 2007, 334, 299.	2.3	930
4	Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes and Endocrinology,the, 2020, 8, 813-822.	11.4	733
5	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2020, 98, S1-S115.	5.2	692
6	Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes and Endocrinology,the, 2020, 8, 546-550.	11.4	680
7	Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 823-833.	11.4	677
8	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation, 2017, 136, 249-259.	1.6	672
9	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	27.0	641
10	New-Onset Diabetes in Covid-19. New England Journal of Medicine, 2020, 383, 789-790.	27.0	624
11	Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis. BMJ: British Medical Journal, 2010, 341, c4229-c4229.	2.3	584
12	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	27.0	526
13	Clinical Inertia in People With Type 2 Diabetes. Diabetes Care, 2013, 36, 3411-3417.	8.6	508
14	Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ, The, 2021, 372, n693.	6.0	494
15	Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ, The, 2020, 371, m3731.	6.0	471
16	Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine, 2020, 29-30, 100630.	7.1	454
17	Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations. Diabetes Care, 2014, 37, 922-933.	8.6	448
18	The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine, 2020, 23, 100404.	7.1	442

#	Article	IF	CITATIONS
19	Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy, 2018, 35, 1763-1774.	2.9	424
20	Is ethnicity linked to incidence or outcomes of covid-19?. BMJ, The, 2020, 369, m1548.	6.0	408
21	Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet, The, 2011, 378, 156-167.	13.7	406
22	Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 965-967.	3.6	390
23	Association of Sedentary Behaviour with Metabolic Syndrome: A Meta-Analysis. PLoS ONE, 2012, 7, e34916.	2.5	388
24	Ethnicity and COVID-19: an urgent public health research priority. Lancet, The, 2020, 395, 1421-1422.	13.7	388
25	Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ: British Medical Journal, 2009, 339, b4731-b4731.	2.3	374
26	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. Journal of the American College of Cardiology, 2018, 71, 2628-2639.	2.8	370
27	Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet, The, 2021, 397, 1711-1724.	13.7	332
28	Prevalence of coâ€morbidities and their association with mortality in patients with <scp>COVID</scp> â€19: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1915-1924.	4.4	320
29	Efficacy and safety of glucagonâ€like peptideâ€1 receptor agonists in type 2 diabetes: <scp>A</scp> systematic review and mixedâ€treatment comparison analysis. Diabetes, Obesity and Metabolism, 2017, 19, 524-536.	4.4	305
30	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	27.0	299
31	Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes and Endocrinology,the, 2019, 7, 385-396.	11.4	298
32	Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 2015, 38, 316-322.	8.6	276
33	Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ, The, 2012, 344, e2333-e2333.	6.0	268
34	Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes, Obesity and Metabolism, 2018, 20, 427-437.	4.4	247
35	Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ: British Medical Journal, 2008, 336, 1180-1185.	2.3	239
36	Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes and Endocrinology,the, 2018, 6, 130-142.	11.4	233

#	Article	IF	CITATIONS
37	Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study. Diabetes Care, 2016, 39, 130-138.	8.6	229
38	Quality of Care of People With Type 2 Diabetes in Eight European Countries. Diabetes Care, 2013, 36, 2628-2638.	8.6	215
39	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 27-35.	11.4	215
40	Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care, 2015, 38, 1449-1455.	8.6	214
41	Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 100.	6.8	206
42	Epidemiology and determinants of type 2 diabetes in south Asia. Lancet Diabetes and Endocrinology,the, 2018, 6, 966-978.	11.4	171
43	Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Primary Care Diabetes, 2017, 11, 3-12.	1.8	170
44	Effectiveness of a Pragmatic Education Program Designed to Promote Walking Activity in Individuals With Impaired Glucose Tolerance. Diabetes Care, 2009, 32, 1404-1410.	8.6	169
45	Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a UK Biobank observational study. European Heart Journal, 2017, 38, 3232-3240.	2.2	168
46	Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes, Obesity and Metabolism, 2018, 20, 488-496.	4.4	167
47	COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care, 2021, 44, 2645-2655.	8.6	164
48	Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE, 2015, 10, e0126427.	2.5	161
49	Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20â€year retrospective cohort study. Clinical Endocrinology, 2013, 78, 926-934.	2.4	156
50	COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes and Endocrinology,the, 2021, 9, 786-798.	11.4	155
51	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovascular Diabetology, 2018, 17, 150.	6.8	149
52	Sedentary Time and Markers of Chronic Low-Grade Inflammation in a High Risk Population. PLoS ONE, 2013, 8, e78350.	2.5	148
53	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. Diabetes Care, 2020, 43, 1695-1703.	8.6	147
54	Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis. Diabetes Care, 2017, 40, 1588-1596.	8.6	143

#	Article	IF	CITATIONS
55	Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health and Quality of Life Outcomes, 2013, 11, 90.	2.4	142
56	Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes and Endocrinology,the, 2021, 9, 293-303.	11.4	140
57	The association between depression and healthâ€related quality of life in people with type 2 diabetes: a systematic literature review. Diabetes/Metabolism Research and Reviews, 2010, 26, 75-89.	4.0	138
58	Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study. EClinicalMedicine, 2020, 25, 100466.	7.1	129
59	The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLoS ONE, 2015, 10, e0126769.	2.5	127
60	Diabetes education and self-management for ongoing and newly diagnosed (DESMOND): Process modelling of pilot study. Patient Education and Counseling, 2006, 64, 369-377.	2.2	122
61	Ethnic Disparities in Diabetes Management and Pay-for-Performance in the UK: The Wandsworth Prospective Diabetes Study. PLoS Medicine, 2007, 4, e191.	8.4	117
62	Educational Interventions in Kidney Disease Care: A Systematic Review of Randomized Trials. American Journal of Kidney Diseases, 2008, 51, 933-951.	1.9	116
63	Self-Reported Sitting Time and Markers of Inflammation, Insulin Resistance, and Adiposity. American Journal of Preventive Medicine, 2012, 42, 1-7.	3.0	116
64	Early Outcomes From the English National Health Service Diabetes Prevention Programme. Diabetes Care, 2020, 43, 152-160.	8.6	116
65	Ethnic differences in SARS-CoV-2 vaccine hesitancy in United Kingdom healthcare workers: Results from the UK-REACH prospective nationwide cohort study. Lancet Regional Health - Europe, The, 2021, 9, 100180.	5.6	116
66	Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 2018, 137, 137-148.	2.8	114
67	SGLT-2 Inhibitors and Cardiovascular Risk. Journal of the American College of Cardiology, 2018, 71, 2497-2506.	2.8	113
68	Preventing the progression to Type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice, 2015, 107, 320-331.	2.8	112
69	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 385-394.	3.9	110
70	Patterns of Multimorbidity in Middle-Aged and Older Adults: An Analysis of the UK Biobank Data. Mayo Clinic Proceedings, 2018, 93, 857-866.	3.0	105
71	Cardiovascular events and allâ€cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: <scp>A B</scp> ayesian metaâ€analysis of survival data. Diabetes, Obesity and Metabolism, 2017, 19, 329-335.	4.4	104
72	Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in <scp>E</scp> urope and the <scp>USA</scp> . Diabetes, Obesity and Metabolism, 2017, 19, 1155-1164.	4.4	100

#	Article	IF	CITATIONS
73	Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881984469.	3.2	100
74	Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities. Journal of Epidemiology and Community Health, 2021, 75, 970-974.	3.7	100
75	Intensity Thresholds on Raw Acceleration Data: Euclidean Norm Minus One (ENMO) and Mean Amplitude Deviation (MAD) Approaches. PLoS ONE, 2016, 11, e0164045.	2.5	96
76	Screening, evaluation and management of depression in people with diabetes in primary care. Primary Care Diabetes, 2013, 7, 1-10.	1.8	91
77	Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ, The, 2012, 345, e4624-e4624.	6.0	87
78	Empowering patients with diabetes: a qualitative primary care study focusing on South Asians in Leicester, UK. Family Practice, 2005, 22, 647-652.	1.9	84
79	A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let's Prevent Diabetes cluster randomised controlled trial. Preventive Medicine, 2016, 84, 48-56.	3.4	83
80	Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes and Endocrinology,the, 2018, 6, 821-832.	11.4	83
81	Associations of mutually exclusive categories of physical activity and sedentary time with markers of cardiometabolic health in English adults: a cross-sectional analysis of the Health Survey for England. BMC Public Health, 2015, 16, 25.	2.9	81
82	Accuracy of Posture Allocation Algorithms for Thigh- and Waist-Worn Accelerometers. Medicine and Science in Sports and Exercise, 2016, 48, 1085-1090.	0.4	80
83	Clinical inertia in management of T2DM. Primary Care Diabetes, 2010, 4, 203-207.	1.8	79
84	Clinical inertia—Time to reappraise the terminology?. Primary Care Diabetes, 2017, 11, 105-106.	1.8	79
85	Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments. Annals of Internal Medicine, 2016, 164, 102.	3.9	70
86	Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. Diabetes, Obesity and Metabolism, 2018, 20, 1337-1341.	4.4	69
87	Ethnicity, household composition and COVID-19 mortality: a national linked data study. Journal of the Royal Society of Medicine, 2021, 114, 182-211.	2.0	69
88	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 606-615.	11.4	67
89	COVID-19 and ethnicity: who will research results apply to?. Lancet, The, 2020, 395, 1955-1957.	13.7	66
90	Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England. European Journal of Epidemiology, 2021, 36, 605-617.	5.7	66

#	Article	IF	CITATIONS
91	Rates of myocardial infarction and stroke in patients initiating treatment with <scp>SGLT</scp> 2â€inhibitors versus other glucoseâ€lowering agents in realâ€world clinical practice: <scp>R</scp> esults from the <scp>CVDâ€REAL</scp> study. Diabetes, Obesity and Metabolism, 2018, 20, 1983-1987.	4.4	65
92	Therapeutic inertia in patients treated with two or more antidiabetics in primary care: <scp>F</scp> actors predicting intensification of treatment. Diabetes, Obesity and Metabolism, 2018, 20, 103-112.	4.4	65
93	Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action. Trials, 2021, 22, 880.	1.6	65
94	Associations Between Sedentary Behaviors and Cognitive Function: Cross-Sectional and Prospective Findings From the UK Biobank. American Journal of Epidemiology, 2018, 187, 441-454.	3.4	64
95	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. Diabetes Research and Clinical Practice, 2019, 151, 20-32.	2.8	63
96	SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Primary Care Diabetes, 2018, 12, 265-283.	1.8	62
97	Causality between nonâ€alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A metaâ€analysis with bias analysis. Liver International, 2019, 39, 557-567.	3.9	62
98	Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. Diabetes Research and Clinical Practice, 2020, 165, 108266.	2.8	62
99	A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: Modelling study. Diabetes Research and Clinical Practice, 2012, 97, 505-513.	2.8	60
100	Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. Journal of Public Health, 2022, 44, 234-245.	1.8	60
101	Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial. Diabetes Care, 2014, 37, 2015-2023.	8.6	56
102	A Randomised Controlled Trial to Reduce Sedentary Time in Young Adults at Risk of Type 2 Diabetes Mellitus: Project STAND (Sedentary Time ANd Diabetes). PLoS ONE, 2015, 10, e0143398.	2.5	56
103	Sedentary Sphere. Medicine and Science in Sports and Exercise, 2016, 48, 748-754.	0.4	55
104	Effects of blood pressure and lipid lowering on cognition. Neurology, 2019, 92, e1435-e1446.	1.1	54
105	Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 130, 121-129.	2.8	53
106	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. Annals of Internal Medicine, 2020, 172, 541.	3.9	53
107	COVID-19 and Diabetes. Annual Review of Medicine, 2022, 73, 129-147.	12.2	52
108	Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001061.	2.8	50

#	Article	IF	CITATIONS
109	Clinical management of type 2 diabetes in south Asia. Lancet Diabetes and Endocrinology,the, 2018, 6, 979-991.	11.4	49
110	Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. Clinical Diabetes, 2020, 38, 371-381.	2.2	49
111	Walking away from type 2 diabetes: trial protocol of a cluster randomised controlled trial evaluating a structured education programme in those at high risk of developing type 2 diabetes. BMC Family Practice, 2012, 13, 46.	2.9	48
112	Association of Sitting Time and Physical Activity With CKD: A Cross-sectional Study in Family Practices. American Journal of Kidney Diseases, 2012, 60, 583-590.	1.9	48
113	COVID-19 and ethnicity: A novel pathophysiological role for inflammation. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1043-1051.	3.6	48
114	SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study. PLoS Medicine, 2021, 18, e1003823.	8.4	48
115	Barriers and Facilitators to Healthy Lifestyle Changes in Minority Ethnic Populations in the UK: a Narrative Review. Journal of Racial and Ethnic Health Disparities, 2017, 4, 1107-1119.	3.2	47
116	Ethnicity and Quality of Diabetes Care in a Health System with Universal Coverage: Population-Based Cross-sectional Survey in Primary Care. Journal of General Internal Medicine, 2007, 22, 1317-1320.	2.6	46
117	Efficacy and tolerability of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1035-1046.	4.4	46
118	Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: A cross-sectional analysis of the ADDITION-Europe trial cohort. Diabetes Research and Clinical Practice, 2014, 104, 281-287.	2.8	45
119	Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review. Clinical Medicine Insights: Endocrinology and Diabetes, 2015, 8, CMED.S20906.	1.9	45
120	Comparison of body mass index at diagnosis of diabetes in a multiâ€ethnic population: <scp>A</scp> caseâ€eontrol study with matched nonâ€diabetic controls. Diabetes, Obesity and Metabolism, 2017, 19, 1014-1023.	4.4	45
121	Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes and Endocrinology,the, 2021, 9, 671-680.	11.4	45
122	Rationale, design and baseline data from the Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: A randomized controlled trial. Patient Education and Counseling, 2008, 73, 264-271.	2.2	44
123	Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia. Lancet Diabetes and Endocrinology,the, 2018, 6, 992-1002.	11.4	43
124	Obesity, walking pace and risk of severe COVID-19 and mortality: analysis of UK Biobank. International Journal of Obesity, 2021, 45, 1155-1159.	3.4	43
125	Comparative Relevance of Physical Fitness and Adiposity on Life Expectancy. Mayo Clinic Proceedings, 2019, 94, 985-994.	3.0	42
126	Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K BMC Infectious Diseases, 2021, 21, 908.	2.9	41

#	Article	IF	CITATIONS
127	Ethnic-minority groups in England and Wales—factors associated with the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking census and death records. International Journal of Epidemiology, 2021, 49, 1951-1962.	1.9	41
128	Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews. Diabetes Care, 2021, 44, 2790-2811.	8.6	41
129	Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2169-2178.	4.4	40
130	Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes. Diabetes Care, 2018, 41, 2096-2104.	8.6	40
131	Rationale and study design for a randomised controlled trial to reduce sedentary time in adults at risk of type 2 diabetes mellitus: project stand (Sedentary Time ANd diabetes). BMC Public Health, 2011, 11, 908.	2.9	39
132	Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 925-937.	11.4	39
133	Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technology Assessment, 2018, 22, 1-160.	2.8	39
134	Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. Acta Diabetologica, 2017, 54, 209-214.	2.5	38
135	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating secondâ€line therapy after metformin monotherapy: <scp>R</scp> etrospective data for 10 256 individuals from the <scp>U</scp> nited <scp>K</scp> ingdom and <scp>G</scp> ermany. Diabetes, Obesity and Metabolism, 2018. 20. 389-399.	4.4	38
136	Long COVID — metabolic risk factors and novel therapeutic management. Nature Reviews Endocrinology, 2021, 17, 379-380.	9.6	38
137	Associations of reallocating sitting time into standing or stepping with glucose, insulin and insulin sensitivity: a cross-sectional analysis of adults at risk of type 2 diabetes. BMJ Open, 2017, 7, e014267.	1.9	37
138	Changes in HbA1c and weight, and treatment persistence, over the 18Âmonths following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Medicine, 2018, 16, 116.	5.5	36
139	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a secondâ€line therapy: Results from the global DISCOVER study programme. Diabetes, Obesity and Metabolism, 2019, 21, 2474-2485.	4.4	36
140	Who should be prioritised for COVID-19 vaccines?. Lancet, The, 2020, 396, 1732-1733.	13.7	36
141	What have we learnt from "real world―data, observational studies and metaâ€analyses. Diabetes, Obesity and Metabolism, 2018, 20, 47-58.	4.4	35
142	Assessing risk for healthcare workers during the covid-19 pandemic. BMJ, The, 2021, 372, n602.	6.0	35
143	Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK sample. Endocrine Connections, 2017, 6, 323-330.	1.9	34
144	Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVIDâ€19: Analysis of the ISARIC CCPâ€UK Cohort. Obesity, 2021, 29, 1223-1230.	3.0	34

#	Article	IF	CITATIONS
145	Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. Cardiovascular Diabetology, 2012, 11, 56.	6.8	33
146	Fitness Moderates Glycemic Responses to Sitting and Light Activity Breaks. Medicine and Science in Sports and Exercise, 2017, 49, 2216-2222.	0.4	33
147	Assessing the costâ€effectiveness of sodium–glucose cotransporterâ€2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 2364-2374.	4.4	33
148	Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nature Metabolism, 2021, 3, 289-292.	11.9	33
149	Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. Clinical Endocrinology, 2015, 83, 542-549.	2.4	32
150	Addition of or switch to insulin therapy in people treated with glucagonâ€like peptideâ€l receptor agonists: A realâ€world study in 66 583 patients. Diabetes, Obesity and Metabolism, 2017, 19, 108-117.	4.4	32
151	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. European Heart Journal, 2019, 40, 2907-2919.	2.2	32
152	Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 561-570.	11.4	32
153	Has pay for performance improved the management of diabetes in the United Kingdom?. Primary Care Diabetes, 2010, 4, 73-78.	1.8	31
154	Strategies to record and use ethnicity information in routine health data. Nature Medicine, 2022, 28, 1338-1342.	30.7	31
155	Associations of Sedentary Time with Fat Distribution in a High-Risk Population. Medicine and Science in Sports and Exercise, 2015, 47, 1727-1734.	0.4	30
156	The language of ethnicity. BMJ, The, 2020, 371, m4493.	6.0	30
157	The need for improved collection and coding of ethnicity in health research. Journal of Public Health, 2021, 43, e270-e272.	1.8	30
158	Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes. Diabetes Care, 2019, 42, 349-351.	8.6	29
159	Walking pace improves all-cause and cardiovascular mortality risk prediction: A UK Biobank prognostic study. European Journal of Preventive Cardiology, 2020, 27, 1036-1044.	1.8	29
160	A population-based cohort study of obesity, ethnicity and COVID-19 mortality in 12.6 million adults in England. Nature Communications, 2022, 13, 624.	12.8	29
161	What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? An observational study in eight European countries. BMJ Open, 2017, 7, e016180.	1.9	28
162	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a realâ€world setting. Diabetes, Obesity and Metabolism, 2019, 21, 1429-1436.	4.4	28

#	Article	IF	CITATIONS
163	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	2.8	28
164	Healthcare workers' views on mandatory SARS-CoV-2 vaccination in the UK: A cross-sectional, mixed-methods analysis from the UK-REACH study. EClinicalMedicine, 2022, 46, 101346.	7.1	27
165	Joint Prevalence of Diabetes, Impaired Glucose Regulation, Cardiovascular Disease Risk and Chronic Kidney Disease in South Asians and White Europeans. PLoS ONE, 2013, 8, e55580.	2.5	26
166	Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. Diabetologia, 2018, 61, 1592-1602.	6.3	26
167	Clinical inertia versus overtreatment in glycaemic management. Lancet Diabetes and Endocrinology,the, 2018, 6, 266-268.	11.4	26
168	The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): protocol for a prospective longitudinal cohort study of healthcare and ancillary workers in UK healthcare settings. BMJ Open, 2021, 11, e050647.	1.9	26
169	COVID-19 vaccination uptake amongst ethnic minority communities in England: a linked study exploring the drivers of differential vaccination rates. Journal of Public Health, 2023, 45, e65-e74.	1.8	26
170	Mortality risk comparing walking pace to handgrip strength and a healthy lifestyle: A UK Biobank study. European Journal of Preventive Cardiology, 2021, 28, 704-712.	1.8	25
171	The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technology Assessment, 2015, 19, 1-80.	2.8	24
172	Breaking up sedentary time with seated upper body activity can regulate metabolic health in obese highâ€risk adults: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 1732-1739.	4.4	24
173	The importance of the initial period of basal insulin titration in people with diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 722-733.	4.4	24
174	Temporal Trend in Young-Onset Type 2 Diabetes—Macrovascular and Mortality Risk: Study of U.K. Primary Care Electronic Medical Records. Diabetes Care, 2020, 43, 2208-2216.	8.6	24
175	Early lessons from a second COVID-19 lockdown in Leicester, UK. Lancet, The, 2020, 396, e4-e5.	13.7	24
176	The impact of the COVIDâ€19 pandemic on glycaemic control in people with diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1850-1860.	4.4	24
177	Development of a lifestyle intervention using the MRC framework for diabetes prevention in people with impaired glucose regulation. Journal of Public Health, 2016, 38, 493-501.	1.8	23
178	The right place for Sulphonylureas today: Part of †Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus'. Diabetes Research and Clinical Practice, 2019, 157, 107836.	2.8	23
179	Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1255-1268.	3.6	23
180	Comparison of glucoseâ€lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 985-997.	4.4	23

#	Article	IF	CITATIONS
181	PRomotion Of Physical activity through structured Education with differing Levels of ongoing Support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial. Trials, 2015, 16, 289.	1.6	22
182	Rationale and design of a cross-sectional study to investigate and describe the chronotype of patients with type 2 diabetes and the effect on glycaemic control: the CODEC study. BMJ Open, 2019, 9, e027773.	1.9	22
183	First-line treatment for type 2 diabetes: is it too early to abandon metformin?. Lancet, The, 2020, 396, 1705-1707.	13.7	22
184	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3025-3035.	3.6	22
185	Lower risk of hospitalization for heart failure, kidney disease and death with sodiumâ€glucose coâ€transporterâ€2 inhibitors compared with dipeptidyl peptidaseâ€4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. Diabetes, Obesity and Metabolism. 2021. 23. 2207-2214.	4.4	22
186	Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open, 2017, 7, e013851.	1.9	21
187	Self-knowledge of HbA1c in people with Type 2 Diabetes Mellitus and its association with glycaemic control. Primary Care Diabetes, 2017, 11, 414-420.	1.8	21
188	Cohort profile: National Diabetes Audit for England and Wales. Diabetic Medicine, 2021, 38, e14616.	2.3	21
189	Engagement, Retention, and Progression to Type 2 Diabetes: A Retrospective Analysis of the Cluster-Randomised "Let's Prevent Diabetes" Trial. PLoS Medicine, 2016, 13, e1002078.	8.4	21
190	Evaluation of the Clinical and Cost Effectiveness of Intermediate Care Clinics for Diabetes (ICCD): A Multicentre Cluster Randomised Controlled Trial. PLoS ONE, 2014, 9, e93964.	2.5	21
191	Reallocating sitting time to standing or stepping through isotemporal analysis: associations with markers of chronic low-grade inflammation. Journal of Sports Sciences, 2018, 36, 1586-1593.	2.0	20
192	Glycaemic control in patients with type 2 diabetes initiating secondâ€ine therapy: Results from the global DISCOVER study programme. Diabetes, Obesity and Metabolism, 2020, 22, 66-78.	4.4	20
193	Ethnic minorities and COVID-19: examining whether excess risk is mediated through deprivation. European Journal of Public Health, 2021, 31, 630-634.	0.3	20
194	Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diabetes Research and Clinical Practice, 2018, 138, 35-43.	2.8	19
195	Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: A UK multisite 12â€month prospective observational study. Diabetes, Obesity and Metabolism, 2019, 21, 1585-1595.	4.4	19
196	Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort. BMC Infectious Diseases, 2021, 21, 717.	2.9	19
197	Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial. Diabetologia. 2013. 56. 2367-2377.	6.3	18
198	Cardiovascular events and mortality in people with and without typeÂ2 diabetes: An observational study in a contemporary multiâ€ethnic population. Journal of Diabetes Investigation, 2021, 12, 1175-1182.	2.4	18

#	Article	IF	CITATIONS
199	Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People With Diabetes in England During the COVID-19 Pandemic. Diabetes Care, 2021, 44, e133-e135.	8.6	18
200	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal, 2021, 42, 2995-3007.	2.2	18
201	A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. Diabetologia, 2021, 64, 1717-1724.	6.3	18
202	Association Between Accelerometer-Assessed Physical Activity and Severity of COVID-19 in UK Biobank. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 997-1007.	2.4	18
203	Sedentary Time and MRIâ€Derived Measures of Adiposity in Active Versus Inactive Individuals. Obesity, 2018, 26, 29-36.	3.0	17
204	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. American Journal of Medicine, 2018, 131, 813-819.e5.	1.5	17
205	Use of MyDesmond digital education programme to support selfâ€management in people with type 2 diabetes during the COVIDâ€19 pandemic. Diabetic Medicine, 2021, 38, e14469.	2.3	17
206	Clustering of comorbidities. Future Healthcare Journal, 2021, 8, e224-e229.	1.4	17
207	Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme. Lancet Diabetes and Endocrinology,the, 2021, 9, 649-651.	11.4	17
208	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. Diabetes Therapy, 2020, 11, 33-48.	2.5	17
209	Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in TypeÂ2 Diabetes. Diabetes Therapy, 2022, 13, 619-634.	2.5	17
210	Investigation of a UK biobank cohort reveals causal associations of self-reported walking pace with telomere length. Communications Biology, 2022, 5, 381.	4.4	17
211	Biochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes. Diabetes Care, 2019, 42, 1132-1135.	8.6	16
212	The present and future scope of realâ€world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?. Diabetes, Obesity and Metabolism, 2020, 22, 21-34.	4.4	16
213	Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Diabetes Care, 2021, 44, 915-924.	8.6	16
214	Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. BMJ Open, 2021, 11, e051237.	1.9	16
215	The impact of the COVID pandemic on primary care diabetes services in the UK: A cross-sectional national survey of views of health professionals delivering diabetes care. Primary Care Diabetes, 2022, 16, 257-263.	1.8	16
216	A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2015, 17, 194-202.	4.4	15

#	Article	IF	CITATIONS
217	Structured education programme for women with polycystic ovary syndrome: a randomised controlled trial. Endocrine Connections, 2018, 7, 26-35.	1.9	15
218	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. Diabetes Therapy, 2019, 10, 1-13.	2.5	15
219	Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large realâ€world studies. Diabetes, Obesity and Metabolism, 2019, 21, 844-853.	4.4	15
220	Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. Diabetologia, 2020, 63, 2129-2139.	6.3	15
221	Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovascular Diabetology, 2021, 20, 159.	6.8	15
222	The development and validation of the Portuguese risk score for detecting type 2 diabetes and impaired fasting glucose. Primary Care Diabetes, 2013, 7, 11-18.	1.8	14
223	Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes. Journal of Diabetes, 2016, 8, 354-362.	1.8	14
224	Risk factors and outcome differences in hypoglycaemiaâ€related hospital admissions: <scp>A</scp> caseâ€control study in <scp>E</scp> ngland. Diabetes, Obesity and Metabolism, 2017, 19, 1371-1378.	4.4	14
225	Associations of Physical Activity Intensities with Markers of Insulin Sensitivity. Medicine and Science in Sports and Exercise, 2017, 49, 2451-2458.	0.4	14
226	Therapeutic inertia amongst general practitioners with interest in diabetes. Primary Care Diabetes, 2018, 12, 87-91.	1.8	14
227	Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study. BMJ Open Diabetes Research and Care, 2019, 7, e000627.	2.8	14
228	Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?. Pharmaceuticals, 2020, 13, 427.	3.8	14
229	Evaluation of the Diabetes Screening Component of a National Cardiovascular Risk Assessment Programme in England: a Retrospective Cohort Study. Scientific Reports, 2020, 10, 1231.	3.3	14
230	Promoting physical activity in a multi-ethnic population at high risk of diabetes: the 48-month PROPELS randomised controlled trial. BMC Medicine, 2021, 19, 130.	5.5	14
231	Association between household size and COVID-19: A UK Biobank observational study. Journal of the Royal Society of Medicine, 2022, 115, 138-144.	2.0	14
232	Feasibility of a structured group education session to improve self-management of blood pressure in people with chronic kidney disease: an open randomised pilot trial. BMJ Open, 2011, 1, e000381-e000381.	1.9	13
233	Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Canadian Journal of Cardiology, 2018, 34, 38-44.	1.7	13
234	The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help?. Diabetes Research and Clinical Practice, 2018, 139, 392-399.	2.8	13

#	Article	IF	CITATIONS
235	Predictors of the Acute Postprandial Response to Breaking Up Prolonged Sitting. Medicine and Science in Sports and Exercise, 2020, 52, 1385-1393.	0.4	13
236	Comparative effectiveness of gliclazide modified release versus sitagliptin as secondâ€line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2417-2426.	4.4	13
237	Missed Opportunities for Timely Recognition of Chronic Limb Threatening Ischaemia in Patients Undergoing a Major Amputation: A Population Based Cohort Study Using the UK's Clinical Practice Research Datalink. European Journal of Vascular and Endovascular Surgery, 2020, 60, 703-710.	1.5	13
238	A randomized, openâ€label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1187-1196.	4.4	13
239	Change in Sedentary Time, Physical Activity, Bodyweight, and HbA1c in High-Risk Adults. Medicine and Science in Sports and Exercise, 2017, 49, 1120-1125.	0.4	13
240	The impact of COVID-19 on primary care: Insights from the National Health Service (NHS) and future recommendations. Journal of Family Medicine and Primary Care, 2021, 10, 4345.	0.9	13
241	The European EUCCLID pilot study on care and complications in an unselected sample of people with type 2 diabetes in primary care. Primary Care Diabetes, 2010, 4, 17-23.	1.8	12
242	Adverse Responses and Physical Activity. Medicine and Science in Sports and Exercise, 2014, 46, 1617-1623.	0.4	12
243	Results from the UK cohort of SOLVE: Providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Primary Care Diabetes, 2014, 8, 57-63.	1.8	12
244	Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. Diabetes Research and Clinical Practice, 2018, 146, 76-84.	2.8	12
245	<p>Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening</p> . Patient Preference and Adherence, 2019, Volume 13, 537-547.	1.8	12
246	Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy. Journal of Clinical Epidemiology, 2019, 106, 98-107.	5.0	12
247	Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes. Diabetes Care, 2021, 44, e32-e34.	8.6	12
248	A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. Health Technology Assessment, 2016, 20, 1-86.	2.8	12
249	A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. Programme Grants for Applied Research, 2017, 5, 1-290.	1.0	12
250	Open science communication: The first year of the UK's Independent Scientific Advisory Group for Emergencies. Health Policy, 2022, 126, 234-244.	3.0	12
251	Validating the QCOVID risk prediction algorithm for risk of mortality from COVID-19 in the adult population in Wales, UK International Journal of Population Data Science, 2020, 5, 1697.	0.1	12
252	Sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. Diabetes, Obesity and Metabolism, 2022, 24, 1187-1196.	4.4	12

#	Article	IF	CITATIONS
253	Prevention of diabetes: A reality in primary care?. Primary Care Diabetes, 2007, 1, 119-121.	1.8	11
254	Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. British Journal of General Practice, 2014, 64, e208-e216.	1.4	11
255	Using an interactive DVD about type 2 diabetes and insulin therapy in a UK South Asian community and in patient education and healthcare provider training. Patient Education and Counseling, 2015, 98, 1123-1130.	2.2	11
256	Relevance of physical function in the association of red and processed meat intake with all–cause, cardiovascular, and cancer mortality. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1308-1315.	2.6	11
257	Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more nonâ€insulin antidiabetic drugs in a realâ€world setting. Diabetes, Obesity and Metabolism, 2019, 21, 1373-1380.	4.4	11
258	Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. Canadian Journal of Diabetes, 2019, 43, 384-391.	0.8	11
259	Intensive versus standard multifactorial cardiovascular risk factor control in screenâ€detected type 2 diabetes: 5â€year and longerâ€term modelled outcomes of the ADDITION‣eicester study. Diabetes/Metabolism Research and Reviews, 2019, 35, e3111.	4.0	11
260	Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT). Diabetes Care, 2021, 44, 1419-1425.	8.6	11
261	Screening for glucose intolerance and development of a lifestyle education programme for prevention of type 2 diabetes in a population with intellectual disabilities: the STOP Diabetes research project. Programme Grants for Applied Research, 2017, 5, 1-316.	1.0	11
262	Indirect effects of the COVID-19 pandemic on people with type 2 diabetes: time to urgently move into a recovery phase. BMJ Quality and Safety, 2022, 31, 483-485.	3.7	11
263	The Reversal Intervention for Metabolic Syndrome (TRIMS) study: rationale, design, and baseline data. Trials, 2011, 12, 107.	1.6	10
264	Optimizing management of glycaemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 397-411.	4.7	10
265	The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?. Primary Care Diabetes, 2018, 12, 383-392.	1.8	10
266	Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A realâ€world study of patients followed for up to 19 years. Diabetes, Obesity and Metabolism, 2021, 23, 218-227.	4.4	10
267	Temporal trends in coâ€morbidities and cardiometabolic risk factors at the time of type 2 diabetes diagnosis in the <scp>UK</scp> . Diabetes, Obesity and Metabolism, 2021, 23, 1150-1161.	4.4	10
268	Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Realâ€world evidence from primary care. Diabetes, Obesity and Metabolism, 2021, 23, 1518-1531.	4.4	10
269	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke, 2021, 52, 2494-2501.	2.0	10
270	Individual, healthcare professional and systemâ€level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and metaâ€ethnography. Diabetic Medicine, 2022, 39, e14678.	2.3	10

#	Article	IF	CITATIONS
271	Framework to aid analysis and interpretation of ongoing COVID-19 research. Wellcome Open Research, 0, 5, 208.	1.8	10
272	Covid-19 and ethnicity: we must seek to understand the drivers of higher transmission. BMJ, The, 2021, 375, n2709.	6.0	10
273	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart, 2022, 108, 1200-1208.	2.9	10
274	New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 Diabetes. Endocrine Practice, 2022, 28, 811-821.	2.1	10
275	Reducing sedentary time in adults at risk of type 2 diabetes: process evaluation of the STAND (Sedentary Time ANd Diabetes) RCT. BMC Public Health, 2017, 17, 80.	2.9	9
276	Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (<scp>SARSâ€CoV</scp> â€2 or <scp>COVID</scp> â€19). Diabetes, Obesity and Metabolism, 2020, 22, 1942-1945.	4.4	9
277	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?. Primary Care Diabetes, 2021, 15, 59-68.	1.8	9
278	United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): a retrospective cohort study using linked routinely collected data, study protocol. BMJ Open, 2021, 11, e046392.	1.9	9
279	A cluster randomized controlled trial of the effectiveness and cost-effectiveness of Intermediate Care Clinics for Diabetes (ICCD): study protocol for a randomized controlled trial. Trials, 2012, 13, 164.	1.6	8
280	Medication burden in the first 5â€years following diagnosis of type 2 diabetes: findings from the <i>ADDITION-UK</i> trial cohort. BMJ Open Diabetes Research and Care, 2015, 3, e000075.	2.8	8
281	Comment on Suissa. Lower Risk of Death With SCLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10. Diabetes Care, 2018, 41, e106-e108.	8.6	8
282	Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study. Journal of Clinical and Translational Endocrinology, 2020, 20, 100225.	1.4	8
283	Dose distribution and upâ€ŧitration patterns of metformin monotherapy in patients with type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2020, 3, e00107.	2.4	8
284	Comparing 24 h physical activity profiles: Office workers, women with a history of gestational diabetes and people with chronic disease condition(s). Journal of Sports Sciences, 2021, 39, 219-226.	2.0	8
285	Focused action is required to protect ethnic minority populations from COVID-19 post-lockdown. British Journal of General Practice, 2021, 71, 37-40.	1.4	8
286	Diabetes prevention: A call to action. Indian Journal of Medical Research, 2011, 134, 579.	1.0	8
287	New drug treatments versus structured education programmes for type 2 diabetes: comparing cost-effectiveness. Lancet Diabetes and Endocrinology,the, 2016, 4, 557-559.	11.4	7
288	Exploring the characteristics of suboptimally controlled patients after 24 weeks of basal insulin treatment: An individualized approach to intensification. Diabetes Research and Clinical Practice, 2017, 123, 209-217.	2.8	7

#	Article	IF	CITATIONS
289	Does the presence of diabetes mellitus confer an increased risk of stroke in patients with atrial fibrillation on direct oral anticoagulants? A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1725-1733.	3.6	7
290	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. Frontiers in Endocrinology, 2021, 12, 708372.	3.5	7
291	Ethnic, social and multimorbidity disparities in therapeutic inertia: A <scp>UK</scp> primary care observational study in patients newly diagnosed with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2437-2445.	4.4	7
292	Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT. Health Technology Assessment, 2021, 25, 1-190.	2.8	7
293	Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of) Tj ETQq1	1 0 <mark>.7</mark> 8431	.4 rgBT /Ove
294	Glucose dysregulation phenotypes — time to improve outcomes. Nature Reviews Endocrinology, 2018, 14, 632-633.	9.6	6
295	Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and allâ€cause mortality: An observational analysis of the ADDITIONâ€Europe trial. Diabetes, Obesity and Metabolism, 2021, 23, 730-741.	4.4	6
296	Gait Speed as a Predictor for Diabetes Incidence in People with or at Risk of Knee Osteoarthritis: A Longitudinal Analysis from the Osteoarthritis Initiative. International Journal of Environmental Research and Public Health, 2021, 18, 4414.	2.6	6
297	Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102484.	3.6	6
298	Efficacy of COVID-19 vaccines by race and ethnicity. Public Health, 2022, , .	2.9	6
299	Screening for diabetes: what do the results of the ADDITION trial mean for clinical practice?. Diabetes Management, 2013, 3, 367-378.	0.5	5
300	COVID-19, ethnicity and cardiometabolic disease self-management in UK primary care. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 2241-2243.	3.6	5
301	Cardiovascular outcome trials of glucose-lowering therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 237-249.	1.4	5
302	Association and relative importance of multiple risk factor control on cardiovascular disease, end-stage renal disease and mortality in people with type 2 diabetes: A population-based retrospective cohort study. Primary Care Diabetes, 2021, 15, 218-226.	1.8	5
303	COVID-19 and the new variant strain in England – What are the implications for those from ethnic minority groups?. EClinicalMedicine, 2021, 33, 100805.	7.1	5
304	Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion. Diabetes Therapy, 2021, 12, 1491-1501.	2.5	5
305	The effectiveness of a structured group education programme for people with established type 2 diabetes in a multi-ethnic population in primary care: A cluster randomised trial. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1549-1559.	2.6	5
306	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). Therapeutics and Clinical Risk Management, 2017, Volume 13, 1569-1576.	2.0	4

#	Article	IF	CITATIONS
307	Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. American Journal of Cardiovascular Drugs, 2018, 18, 13-24.	2.2	4
308	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. BMJ Open, 2018, 8, e023206.	1.9	4
309	Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017. JAMA Network Open, 2019, 2, e1916447.	5.9	4
310	Should sodiumâ€glucose coâ€transporterâ€2 inhibitors be considered as firstâ€line oral therapy for people with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2019, 21, 207-209.	4.4	4
311	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. Lancet Diabetes and Endocrinology,the, 2020, 8, 810-811.	11.4	4
312	Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2020, 165, 108250.	2.8	4
313	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A populationâ€based observational retrospective cohort study. Diabetic Medicine, 2022, 39, e14697.	2.3	4
314	Normative wrist-worn accelerometer values for self-paced walking and running: a walk in the park. Journal of Sports Sciences, 2021, , 1-8.	2.0	4
315	Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. Diabetes Care, 2022, 45, 1132-1140.	8.6	4
316	Significant reduction in chronic kidney disease progression with sodiumâ€glucose cotransporterâ€2 inhibitors compared to dipeptidyl peptidaseâ€4 inhibitors in adults with type 2 diabetes in a <scp>UK</scp> clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 2138-2147.	4.4	4
317	Predictors and determinants of albuminuria in people with prediabetes and diabetes based on smoking status: A cross-sectional study using the UK Biobank data. EClinicalMedicine, 2022, 51, 101544.	7.1	4
318	Diabetes advice for women with polycystic ovary syndrome: prevention, prevention, prevention. Diabetes Management, 2013, 3, 467-480.	0.5	3
319	Individualised targets for insulin initiation in type 2 diabetes mellitus—the influence of physician and practice: a cross-sectional study in eight European countries. BMJ Open, 2019, 9, e032040.	1.9	3
320	Development, content validation, and reliability of the Assessment of Real-World Observational Studies (ArRoWS) critical appraisal tool. Annals of Epidemiology, 2021, 55, 57-63.e15.	1.9	3
321	EXTending availability of self-management structured EducatioN programmes for people with type 2 Diabetes in low-to-middle income countries (EXTEND)—a feasibility study in Mozambique and Malawi. BMJ Open, 2021, 11, e047425.	1.9	3
322	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2021, 180, 108974.	2.8	3
323	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. Journal of Diabetes and Its Complications, 2021, 35, 108077.	2.3	3
324	Life expectancy by ethnic group in England. BMJ, The, 2021, 375, e068537.	6.0	3

#	Article	IF	CITATIONS
325	Type 2 diabetes: lifetime risk of advancing from prediabetes. Lancet Diabetes and Endocrinology,the, 2016, 4, 5-6.	11.4	2
326	Let's Prevent Diabetes: from idea to implementation. Practical Diabetes, 2017, 34, 55-57.	0.3	2
327	Screening for Diabetes and Prediabetes. Endocrinology, 2018, , 369-400.	0.1	2
328	Effects of an Electronic Software "Prompt―With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomized Trial. Diabetes Care, 2020, 43, 1893-1901.	8.6	2
329	Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study. Diabetes Research and Clinical Practice, 2021, 171, 108616.	2.8	2
330	Dashboards to reduce inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care sentinel network. Primary Care Diabetes, 2021, 15, 1075-1079.	1.8	2
331	Metformin for Preventing Type 2 Diabetes Mellitus in Women with a Previous Diagnosis of Gestational Diabetes: A Narrative Review. Seminars in Reproductive Medicine, 2020, 38, 366-376.	1.1	2
332	Ethnicity and prognosis following a cardiovascular event in people with and without type 2 diabetes: Observational analysis in over 5 million subjects in England. Diabetes Research and Clinical Practice, 2022, 189, 109967.	2.8	2
333	Response to Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417. Diabetes Care, 2014, 37, e114-e114.	8.6	1
334	Insulin degludec – The impact of a new basal insulin on care in type 2 diabetes. Primary Care Diabetes, 2014, 8, 119-125.	1.8	1
335	Screening for Diabetes and Prediabetes. Endocrinology, 2018, , 1-33.	0.1	1
336	Polycystic ovary syndrome: An underestimated problem in primary care. International Journal of Clinical Practice, 2018, 72, e13081.	1.7	1
337	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. Canadian Journal of Cardiology, 2019, 35, 644-652.	1.7	1
338	Editorial: Studies in young adults with type 2 diabetes to inform evidence-based guidelines specifically for early-onset type 2 diabetes are urgently required. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1905-1906.	3.6	1
339	Durability of glycaemic control in patients with type 2 diabetes after metformin failure: Prognostic model derivation and validation using the DISCOVER study. Diabetes, Obesity and Metabolism, 2020, 22, 828-837.	4.4	1
340	The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e152.	1.0	1
341	Introduction: Real-World Evidence in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 29-32.	2.5	1
342	From the United Kingdom to Australia—Adapting a Web-Based Self-management Education Program to Support the Management of Type 2 Diabetes: Tutorial. Journal of Medical Internet Research, 2022, 24, e26339.	4.3	1

#	Article	IF	CITATIONS
343	Predictors of adverse outcome in the first and second waves of the COVID-19 pandemic: results from a UK centre. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612210745.	1.8	1
344	The authors reply:. Kidney International, 2022, 101, 420-421.	5.2	1
345	Association of Ethnicity and Socioeconomic Status With COVID-19 Hospitalization and Mortality in Those With and Without Chronic Kidney Disease. Kidney International Reports, 2022, 7, 334-338.	0.8	1
346	Standing up to diabetes: sedentary behavior matters. Diabetes Management, 2012, 2, 261-263.	0.5	0
347	Sodiumâ€glucose coâ€ŧransporterâ€2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: <scp>F</scp> rom efficacy to effectiveness. Diabetes, Obesity and Metabolism, 2018, 20, 763-765.	4.4	0
348	Quantifying the association between ethnicity and COVID-19 mortality: a national cohort study protocol. BMJ Open, 2021, 11, e045286.	1.9	0
349	Ethnic differences in the relationship between step cadence and physical function in older adults. Journal of Sports Sciences, 2022, 40, 1183-1190.	2.0	0
350	Cardiovascular and renal outcomes of initial combination therapy with glucoseâ€lowering agents versus a stepwise approach in newly diagnosed or treatmentâ€naÃ⁻ve type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1469-1482.	4.4	0
351	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 1734-1740.	4.4	0